Five things to watch as the Biosimilars market heats up in 2022
pharmaphorum
APRIL 1, 2022
market is just beginning to heat up. And already in the first quarter of 2022, the FDA approved a third filgrastim biosimilar, Releuko. With 34 approved biosimilars and dozens more in the pipeline, what does this year have in store? Innovator products working to maintain market share.
Let's personalize your content